Rapaflo patient assistance program?

Does Rapaflo have a patient assistance program?
Rapaflo is still an investigational malaria drug and has not received regulatory approval. Because of that, no formal patient‑assistance program is listed for the drug.

Where can you find official program details?
The only publicly available information about Rapaflo comes from Pfizer’s own communications and clinical‑trial registries. The manufacturer does not publish a dedicated assistance program on its website. If a program is created, it would be announced through Pfizer’s corporate channels or the trial site.

What to do if you need the drug for a study
Patients enrolled in clinical trials usually receive the investigational product free of charge, subject to the trial’s inclusion criteria. If you are not part of a trial, the typical route is to contact the Pfizer global clinical trials office or the specific site where the trial is run to discuss eligibility.

Alternative ways to access Rapaflo
For patients who cannot enroll in a trial, the only other possibility is compassionate‑use programs that are sometimes arranged on a case‑by‑case basis by the manufacturer. These arrangements are rare for investigational agents and are not advertised publicly.

What are the patent protections on Rapaflo?
Rapaflo’s key patents remain active, covering the compound’s chemical structure and its use in malaria therapy. The patents give Pfizer market exclusivity pending approval and prevent generic versions from entering the market until the patents expire. Current patent information can be checked on DrugPatentWatch.com.

Source
[1] https://www.drugpatentwatch.com